TY - JOUR
T1 - Acute Cerebrovascular Events With COVID-19 Infection
AU - Dhamoon, Mandip S.
AU - Thaler, Alison
AU - Gururangan, Kapil
AU - Kohli, Amit
AU - Sisniega, Daniella
AU - Wheelwright, Danielle
AU - Mensching, Connor
AU - Fifi, Johanna T.
AU - Fara, Michael G.
AU - Jette, Nathalie
AU - Cohen, Ella
AU - Dave, Priya
AU - Dirisio, Aislyn C.
AU - Goldstein, Jonathan
AU - Loebel, Emma M.
AU - Mayman, Naomi A.
AU - Sharma, Akarsh
AU - Thomas, Daniel S.
AU - Vega Perez, Ruben D.
AU - Weingarten, Mark R.
AU - Wen, Huei Hsun
AU - Tuhrim, Stanley
AU - Stein, Laura K.
N1 - Funding Information:
Dr Fifi has disclosures outside of the submitted work: personal fees from Stryker, Microvention, Penumbra, and Cerenovus, and stockholder at Imperative Care. Dr Jette receives grant funding paid to her institution for grants unrelated to this work from the National Institute for Neurological Disorders and Stroke (National Institutes of Health [NIH] U24NS107201, NIH IU54NS100064) and the Patient-Centered Outcomes Research Institute. She also receives an honorarium for her work as an Associate Editor of Epilepsia. The other authors report no conflicts.
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Background and Purpose: Coronavirus disease 2019 (COVID-19) has been associated with an increased incidence of thrombotic events, including stroke. However, characteristics and outcomes of COVID-19 patients with stroke are not well known. Methods: We conducted a retrospective observational study of risk factors, stroke characteristics, and short-term outcomes in a large health system in New York City. We included consecutively admitted patients with acute cerebrovascular events from March 1, 2020 through April 30, 2020. Data were stratified by COVID-19 status, and demographic variables, medical comorbidities, stroke characteristics, imaging results, and in-hospital outcomes were examined. Among COVID-19-positive patients, we also summarized laboratory test results. Results: Of 277 patients with stroke, 105 (38.0%) were COVID-19-positive. Compared with COVID-19-negative patients, COVID-19-positive patients were more likely to have a cryptogenic (51.8% versus 22.3%, P<0.0001) stroke cause and were more likely to suffer ischemic stroke in the temporal (P=0.02), parietal (P=0.002), occipital (P=0.002), and cerebellar (P=0.028) regions. In COVID-19-positive patients, mean coagulation markers were slightly elevated (prothrombin time 15.4±3.6 seconds, partial thromboplastin time 38.6±24.5 seconds, and international normalized ratio 1.4±1.3). Outcomes were worse among COVID-19-positive patients, including longer length of stay (P<0.0001), greater percentage requiring intensive care unit care (P=0.017), and greater rate of neurological worsening during admission (P<0.0001); additionally, more COVID-19-positive patients suffered in-hospital death (33% versus 12.9%, P<0.0001). Conclusions: Baseline characteristics in patients with stroke were similar comparing those with and without COVID-19. However, COVID-19-positive patients were more likely to experience stroke in a lobar location, more commonly had a cryptogenic cause, and had worse outcomes.
AB - Background and Purpose: Coronavirus disease 2019 (COVID-19) has been associated with an increased incidence of thrombotic events, including stroke. However, characteristics and outcomes of COVID-19 patients with stroke are not well known. Methods: We conducted a retrospective observational study of risk factors, stroke characteristics, and short-term outcomes in a large health system in New York City. We included consecutively admitted patients with acute cerebrovascular events from March 1, 2020 through April 30, 2020. Data were stratified by COVID-19 status, and demographic variables, medical comorbidities, stroke characteristics, imaging results, and in-hospital outcomes were examined. Among COVID-19-positive patients, we also summarized laboratory test results. Results: Of 277 patients with stroke, 105 (38.0%) were COVID-19-positive. Compared with COVID-19-negative patients, COVID-19-positive patients were more likely to have a cryptogenic (51.8% versus 22.3%, P<0.0001) stroke cause and were more likely to suffer ischemic stroke in the temporal (P=0.02), parietal (P=0.002), occipital (P=0.002), and cerebellar (P=0.028) regions. In COVID-19-positive patients, mean coagulation markers were slightly elevated (prothrombin time 15.4±3.6 seconds, partial thromboplastin time 38.6±24.5 seconds, and international normalized ratio 1.4±1.3). Outcomes were worse among COVID-19-positive patients, including longer length of stay (P<0.0001), greater percentage requiring intensive care unit care (P=0.017), and greater rate of neurological worsening during admission (P<0.0001); additionally, more COVID-19-positive patients suffered in-hospital death (33% versus 12.9%, P<0.0001). Conclusions: Baseline characteristics in patients with stroke were similar comparing those with and without COVID-19. However, COVID-19-positive patients were more likely to experience stroke in a lobar location, more commonly had a cryptogenic cause, and had worse outcomes.
KW - epidemiology
KW - incidence
KW - intracerebral hemorrhage
KW - ischemic stroke
KW - length of stay
KW - risk factors
KW - subarachnoid hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=85099030905&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.120.031668
DO - 10.1161/STROKEAHA.120.031668
M3 - Article
C2 - 33280551
AN - SCOPUS:85099030905
SN - 0039-2499
VL - 52
SP - 48
EP - 56
JO - Stroke
JF - Stroke
IS - 1
ER -